Fresenius SE & Co. KGaA, through its operating company Fresenius Kabi, has entered a partnership with U.S.-based manufacturer Phlow Corp. to create a fully domestic, end-to-end supply chain for Epinephrine Injection, USP. Under the agreement, Phlow will produce the active pharmaceutical ingredient (API) in the United States, while Fresenius Kabi will handle the manufacturing of finished doses for hospitals and clinics nationwide. This collaboration aims to address frequent shortages of this essential medicine and strengthen pharmaceutical security in the U.S. Epinephrine produced through this initiative could become available to U.S. hospitals as early as 2027, pending regulatory approvals.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fresenius SE & Co. KGaA published the original content used to generate this news brief on February 09, 2026, and is solely responsible for the information contained therein.